Induction of chronic epileptiform activity in the rat by an inhibitor of cholesterol synthesis, U18666A.
Earlier work in our and other laboratories suggest that alteration of brain lipids, primarily sterols, could be a precondition for the development of epileptiform activity. The present study further tests this hypothesis by attempting to produce chronic epileptiform activity in the rat by a drug which impairs biosynthesis of cerebral cholesterol. Starting one day after birth, weekly injection of the rat with U18666A, 3-beta(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride (10 mg/kg, s.c.), produced a reduced seizure threshold to flurothyl ether and a recurrent, spontaneous seizure state by the sixth and tenth weeks of life, respectively. These conditions were not seen if treatment was delayed until rats were about 4 weeks old. The seizure pattern, as seen by continuous ECoG and EMG recordings, consisted of a 3--5 sec burst of high voltage spiking and corresponding increases in muscle activity. However, major motor seizures were not produced. The total episode lasted 10--15 sec. Seizure frequency ranged from 5 to 21 per day. U18666A decreases cholesterolsynthesis, presumably by inhibiting enzymatic reduction of desmosterol to cholesterol. After the first two weeks of treatment, cerebral cortical cholesterol levels decreased to about 50% of control cortical levels. However, the concentration of cerebral total sterols did not change because desmosterol levels reciprocally increased. In spite of continued drug dosage, cholesterol and desmosterol levels of treated rats approached those of controls by 8 weeks of age. These observations, plus finding that a seizure-prone state did not develop in rats when the onset of drug treatment was postponed until about 4 weeks of age, suggest that alterations of brain sterols early in development of the mammalian brain can result in development of a chronic, epileptiform condition later in life.
D000367:Age Factors; D000736:Androstenes / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism*; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000378:metabolism* / Q000502:physiology; D002784:Cholesterol / Q000378:metabolism; D002908:Chronic Disease; D003897:Desmosterol / Q000378:metabolism; D004198:Disease Susceptibility; D005481:Flurothyl / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D012640:Seizures / Q000139:chemically induced*
D000736:Androstenes; D000924:Anticholesteremic Agents; D010743:Phospholipids; C006261:3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one; D003897:Desmosterol; D002784:Cholesterol; D005481:Flurothyl